Abstract Number: 137 • 2016 ACR/ARHP Annual Meeting
Imaging Remission By Musculoskeletal Ultrasound Leads to a Better Functional Outcome – Results of the US Impera Study – US 7-Score Implementation Study in Early Rheumatoid Arthritis
Background/Purpose: Novel treat-to-target strategies present new challenges to treatment monitoring in rheumatoid arthritis (RA). To compare functional outcomes in early RA patients monitored by standard…Abstract Number: 1981 • 2016 ACR/ARHP Annual Meeting
A Pilot Pulsed Arterial Spin Labeling Study of Regional Cerebral Blood Flow in Response to Pain in RA, before and after DMARD Treatment
Background/Purpose: Although significant advances have been made in treating inflammation in RA, little is known about central nervous system (CNS) pain pathways in inflammatory arthritis.…Abstract Number: 2578 • 2016 ACR/ARHP Annual Meeting
Plasma Levels of Bone Morphogenetic Protein (BMP) Subgroups and Their Inhibitors (noggin, sclerostin) in Rheumatoid Arthritis Patients and Correlation with Disease Activity, Clinical and Radiographic Progression
Background/Purpose: Progressive bone destruction occurs in rheumatoid arthritis (RA) due to imbalance of osteoblast/osteoclast activity. Bone morphogenetic proteins (BMPs) regenerate bone damage by stimulating the…Abstract Number: 427 • 2015 ACR/ARHP Annual Meeting
The Impact of Biologic Agent Initiation after 1 Versus 2 Prior Csdmards in Patients with Rheumatoid Arthritis
Background/Purpose: Patients with Rheumatoid Arthritis (RA) who don’t respond to conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) should be treated with biologic agents(1). The objective…Abstract Number: 1488 • 2015 ACR/ARHP Annual Meeting
Following the American College of Rheumatology Quality Guidelines Can Enhance the Safety of Rheumatoid Arthritis Patients Treated with Disease Modifying Drugs
Background/Purpose: Adverse events (AEs) and serious adverse events (SAEs) from disease modifying drugs (DMARDs) for Rheumatoid Arthritis (RA) can result in significant morbidity and even…Abstract Number: 2729 • 2015 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcome of Iguratimod for Rheumatoid Arthritis
Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…Abstract Number: 498 • 2015 ACR/ARHP Annual Meeting
Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), the non-adherence to therapy may impair the clinical outcomes, being often associated with the disease flare and…Abstract Number: 1491 • 2015 ACR/ARHP Annual Meeting
Effects of Drug Induced Toxicity on Patient Reported Outcomes in Early Rheumatoid Arthritis Treated-to-Target Using Conventional Triple DMARD Therapy
Background/Purpose: While the introduction of the treat-to-target (T2T) strategy is associated with lower disease activity scores in rheumatoid arthritis (RA), the potential for increased toxicity…Abstract Number: 2731 • 2015 ACR/ARHP Annual Meeting
Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry
Background/Purpose: For patients with rheumatoid arthritis (RA), there are limited real-world data on factors that predict persistency on biologic therapy or whether use of biologics…Abstract Number: 516 • 2015 ACR/ARHP Annual Meeting
Immunological and Ultrasound Characteristics of Patients with Rheumatoid Arthritis in Clinical Remission – Can We Use These to Predict Outcomes?
Background/Purpose: Remission is the key treatment goal in rheumatoid arthritis (RA). Although clinical remission is increasingly achieved, many patients progress both structurally and functionally. We…Abstract Number: 1553 • 2015 ACR/ARHP Annual Meeting
Effect of Drug Therapy on Net Cholesterol Efflux Capacity of HDL-Enriched Serum in Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased coronary heart disease risk. Some RA therapies may modify this risk, but underlying mechanisms are unclear. The…Abstract Number: 2742 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib Monotherapy Versus Combination Therapy in a Latin American Subpopulation of Patients with Rheumatoid Arthritis: A Pooled Phase 3 Analysis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post-hoc pooled analysis was designed to assess the efficacy and safety…Abstract Number: 546 • 2015 ACR/ARHP Annual Meeting
Adipokines and Insulin-like Growth Factor 1 As Predictors of Clinical and Radiographic Outcomes in Early Rheumatoid Arthritis
Background/Purpose: Adipokines are cytokines/hormones primarily synthesized in white adipose tissue. In rheumatoid arthritis (RA), some adipokines have been associated with worse outcomes (1-3). The aim…Abstract Number: 1634 • 2015 ACR/ARHP Annual Meeting
The Effects of Glucocorticoids on the Efficacy of Tofacitinib As Monotherapy and in Combination Therapy with Nonbiologic Dmards: An Analysis of Data from Six Phase 3 Studies
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients with RA often receive concomitant treatment with glucocorticoids (GCs) to control…Abstract Number: 2749 • 2015 ACR/ARHP Annual Meeting
A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Patients (pts) with Rheumatoid Arthritis (RA): Preliminary Results
Background/Purpose: FPA008 is a humanized IgG4 anti-CSF1R antibody that blocks the binding of CSF1 and IL34 ligands to CSF1R, resulting in inhibition of the activation…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 24
- Next Page »